MetaVia Weight Loss, Safety, Potential Best-In-Class Glucose Control, Waist Reduction, Tolerability

MetaVia (NASDAQ: MTVA) announced positive results from its 4-week Phase 1 multiple ascending dose (MAD) trial of DA-1726, a novel dual receptor agonist for obesity treatment. The 32mg dose cohort demonstrated a maximum weight loss of 6.3% and mean weight loss of 4.3% at Day 26 (p=0.0005), with no titration required.

Key findings include:Maximum waist circumference reduction of 3.9 inches and mean reduction of 1.6 inches at Day 33
Maximum lowering of fasted glucose of -18 mg/dL and mean lowering of -5.3 mg/dL
25% of subjects experienced mostly mild gastrointestinal adverse events
No treatment-related discontinuations or serious adverse events



The company plans to conduct Phase 1 Part 3 study investigating DA-1726 on Wegovy early drop-out patients, aiming to demonstrate superior tolerability and safety. Additional cohorts will be added to determine maximum tolerated dose.

https://www.stocktitan.net/news/MTVA/meta-via-announces-positive-top-line-data-from-the-4-week-phase-1-dw1nqblem4ld.html